We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Gold Nanoparticles to Improve Accuracy of Ovarian Cancer Diagnosis

By LabMedica International staff writers
Posted on 11 Sep 2025

Ovarian cancer is considered one of the deadliest cancers, in part because it rarely shows clear symptoms in its early stages, and diagnosis is often complex. More...

Current approaches make it difficult to accurately triage women with ovarian cancer compared to benign conditions, and often require painful, invasive procedures such as tissue biopsies. Researchers have now developed a new nanoparticle-based approach that can highlight ovarian cancer markers more accurately than current diagnostic tools.

A project led by The University of Queensland (Brisbane, Australia) and collaborators has led to the development of a technology that uses sponge-like mesoporous gold nanoparticles to improve cancer diagnostics through their unique biosensing properties. These structures act as light amplifiers, revealing even the faintest traces of cancer markers in patient samples such as urine, saliva, or blood.

Researchers boosted the sensitivity of gold-enhanced light sensors using Surface-Enhanced Raman Scattering (SERS). Compared with commercially available nanoparticles, mesoporous gold increased sensitivity significantly, enabling tiny "hotspots" of light to amplify biomarker signals. Embedded into a diagnostic process with a small tube and handheld Raman spectrophotometer, the method has already outperformed current blood tests, achieving 82% sensitivity in confirming ovarian cancer and 98% specificity in ruling it out. The research was published in the nanoscience and nanotechnology journal Small.

The portability, affordability, and simplicity of this sensor technology make it especially promising for women in remote or under-resourced regions. By transforming disease monitoring, mesoporous nanotechnologies could reduce unnecessary procedures and help pave the way for more personalized treatment strategies. With further development, devices like this could move closer to everyday clinical use, improving survival rates through earlier and more accurate detection.

“This project demonstrates how mesoporous nanotechnologies can help us transform disease monitoring and pave the way for personalized treatment strategies,” said Javeria Bashir, nanomaterials researcher at The University of Queensland and lead developer of the technology. “Devices like this are moving closer and closer to everyday use.”

Related Links:
The University of Queensland


Gold Member
Cardiovascular Risk Test
Metabolic Syndrome Array I & II
Portable Electronic Pipette
Mini 96
Gold Member
Hematology Analyzer
Medonic M32B
Automated Chemiluminescence Immunoassay Analyzer
MS-i3080
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Immunology

view channel
Image: When assessing the same lung biopsy sample, research shows that only 18% of pathologists will agree on a TCMR diagnosis (Photo courtesy of Thermo Fisher)

Molecular Microscope Diagnostic System Assesses Lung Transplant Rejection

Lung transplant recipients face a significant risk of rejection and often require routine biopsies to monitor graft health, yet assessing the same biopsy sample can be highly inconsistent among pathologists.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.